- Home
- KURA vs FLGT Comparison
KURA vs FLGT Comparison
Compare KURA & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 867.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | KURA | FLGT |
|---|---|---|
| Price | $8.35 | $23.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $26.88 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.4M | 192.3K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $104,029,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $88.72 | $16.84 |
| Revenue Next Year | $68.75 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $5.41 | $14.57 |
| 52 Week High | $12.49 | $31.04 |
Technical Indicators
Market Signals| Indicator | KURA | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 25.53 |
| Support Level | $7.50 | $22.39 |
| Resistance Level | $8.08 | $23.49 |
| Average True Range (ATR) | 0.34 | 0.83 |
| MACD | 0.07 | -0.33 |
| Stochastic Oscillator | 68.99 | 15.36 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.